New draft guidance from the US Food and Drug Administration (FDA) includes a series of considerations for researchers designing clinical trials to investigate “classic psychedelics,” such as psilocybin, lysergic acid diethylamide (known as LSD), and methylenedioxymethamphetamine (known as MDMA). Psychedelics, many of which are currently classified as Schedule I controlled substances, have shown promise in recent years for the treatment of medical conditions such as depression, posttraumatic stress disorder, and substance use disorders, according to the FDA’s statement.
Source: JAMA Online First